PDC LINE PHARMA
Biotech company/R&D
www.pdc-line-pharma.com/LIEGE, BelgiumAbout
Sector: Chemicals, Pharmaceuticals and Lifesciences
About PDC*line Pharma
Founded in 2014 as a spin-off of the French Blood Bank (EFS), PDC*line Pharma is a Belgian-French clinical-stage biotech company that develops an innovative class of active immunotherapies for cancers, based on a GMP-grade allogeneic therapeutic cell line of Plasmacytoid Dendritic Cells (PDC_line). PDC_line is much more potent than conventional dendritic cell-based vaccines in priming and boosting antitumor antigen-specific cytotoxic T-cells, including the T-cells specific for neoantigens, and is synergistic with checkpoint inhibitors. The technology can potentially be applied to any type of cancer. Following a first-in-human phase I feasibility study in melanoma, PDC_line Pharma focuses on the development of PDC_lung01, a candidate for Non-Small-Cell Lung Cancer (NSCLC) currently in phase I/II trials, and PDC_neo with neoantigens in preclinical development. The company has a staff of 42, with an experienced management team. It has raised more than €62M in equity and non-dilutive funding. In March 2019, PDC_line Pharma granted an exclusive license to the LG Chem Life Sciences company in South Korea and an exclusive option in other Asian countries, for the development and commercialization of the PDC_lung01 cancer vaccine for lung cancer. The total deal is worth $123M, plus tiered royalties on net sales in Asia.
HEALTH SECTOR
CLINICAL DEVELOPMENT AND TRIALS
MANUFACTURING AND PRODUCTION
SUPPLY CHAIN MANAGEMENT AND LOGISTICS
INVESTMENT AND BUSINESS DEVELOPMENT
THERAPEUTIC AREAS
RESEARCH AND DEVELOPMENT